Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus

Summary

It was the objective of this study to investigate the relation between vitronectin and plasminogen activator inhibitor (PAI)-1 plasma levels with nine-year incidences of the metabolic syndrome (MetS) and of type 2 diabetes mellitus (T2DM). Baseline plasma concentrations of vitronectin and PAI-1 were measured in 627 healthy participants from the prospective D.E.S.I.R. cohort who subsequently developed MetS (n=487) and T2DM (n=182) over a nine-year follow-up (42 presented both) and who were matched with two healthy control subjects each by use of a nested case-control design. Parameters composing the MetS explained about 20% of plasma vitronectin levels. An increase of one standard deviation of vitronectin was associated with increased risks of both the MetS (odds ratio [OR] = 1.21 [1.07 – 1.37], p = 0.003) and T2DM (OR = 1.24 [1.01 – 1.53], p = 0.045). Corresponding ORs for PAI-1 levels were 1.46 [1.27 – 1.68] (p < 10⁻⁴) and 1.40 [1.14 – 1.72] (p = 0.0012). However, the effects of vitronectin and PAI-1 levels on outcomes were not independent. The vitronectin–MetS association was restricted to individuals with low to modest PAI-1 levels (OR = 1.33 [1.14 – 1.54], p = 0.0003) while no association was observed in individuals with high PAI-1 levels (OR = 0.87 [0.68 – 1.10], p = 0.24), the test for interaction being highly significant (p = 0.0009). In conclusion, baseline plasma vitronectin is a marker of incident MetS at nine years. Its predictive ability for MetS and T2DM should not be assessed independently of PAI-1 levels.

Keywords

PAI-1 - vitronectin - metabolic syndrome - diabetes

• References

• 1 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
• 2 Malik S, Wong ND, Franklin SS. et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.
• 3 Hu G, Qiao Q, Tuomilehto J. et al. DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-1076.
• 4 Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?. Diabetologia 2008; 51: 926-940.
• 5 Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
• 6 Mertens I, Verrijken A, Michiels JJ. et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006; 30: 1308-1314.
• 7 Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008; 100: 992-1006.
• 8 Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008; 99: 995-1000.
• 9 Cigolini M, Targher G, Bergamo Andreis IA. et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16: 368-374.
• 10 Meigs JB, Mittleman MA, Nathan DM. et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. J Am Med Assoc 2000; 283: 221-228.
• 11 Gray RP, Panahloo A, Mohamed-Ali V. et al. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction. Atherosclerosis 1997; 130: 171-178.
• 12 Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-2207.
• 13 Ingelsson E, Pencina MJ, Tofler GH. et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007; 116: 984-992.
• 14 Festa A, D’Agostino R, Jr Tracy RP. et al. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type II diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137.
• 15 Festa A, Williams K, Tracy RP. et al. Progression of plasminogen activator in- hibitor-1 and fibrinogen levels in relation to incident type II diabetes. Circulation 2006; 113: 1753-1759.
• 16 Meigs JB, O’donnell CJ, Tofler GH. et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 2006; 55: 530-537.
• 17 Ma L-J, Mao S-L, Taylor KL. et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-346.
• 18 Liang X, Kanjanabuch T, Mao SL. et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab 2006; 290: E103-E113.
• 19 Schäfer K, Fujisawa K, Konstantinides S. et al. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15: 1840-1842.
• 20 Schvartz I, Seger D, Shaltiel S. Vitronectin. Int J Biochem Cell Biol. 1999; 31: 539-44.
• 21 Declerck PJ, De Mol M, Alessi MC. et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-15461.
• 22 Lebrun P, Baron V, Hauck CR. et al. Cell adhesion and focal adhesion kinase regulate insulin receptor substrate-1 expression. J Biol Chem 2000; 275: 38371-38377.
• 23 Dupont DM, Madsen JB, Kristensen T. et al. Biochemical properties of plasminogen activator inhibitor-1. Front Biosci 2009; 14: 1337-1361.
• 24 López-Alemany R, Redondo JM, Nagamine Y. et al. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 2003; 270: 814-821.
• 25 Kaido T, Yebra M, Cirulli V. et al. Impact of defined matrix interactions on insulin production by cultured human beta-cells: effect on insulin content, secretion, and gene transcription. Diabetes 2006; 55: 2723-2729.
• 26 Balkau B, Eschwege E, Tichet J. et al. Proposed criteria for the diagnosis of diabetes: evidence from a French epidemiological study (D.E.S.I.R.). Diabetes Metab 1997; 23: 428-434.
• 27 Grundy SM, Cleeman JI, Daniels SR. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
• 28 Vari IS, Balkau B, Kettaneh A. et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007; 30: 1795-1801.
• 29 Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23: 1038-1039.
• 30 Ekmekci H, Sonmez H, Ekmekci OB. et al. Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J Thromb Thrombolysis 2002; 14: 221-225.
• 31 Derer W, Barnathan ES, Safak E. et al. Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting. Circ Cardiovasc Intervent 2009; 2: 14-19.
• 32 Tollefsen DM, Weigel CJ, Kabeer MH. The presence of methionine or threonine at position 381 in vitronectin is correlated with proteolytic cleavage at arginine 379. J Biol Chem 1990; 265: 9778-9781.
• 33 Chain D, Korc-Grodzicki B, Kreizman T. et al. The phosphorylation of the two-chain form of vitronectin by proteinkinase A is heparin dependent. FEBS Lett 1990; 269: 221-225.
• 34 Chain D, Korc-Grodzicki B, Kreizman T. et al. Endogenous cleavage of the Arg-379-Ala-380 bond in vitronectin results in adistinct conformational change which ‘buries’ Ser-378, its site of phosphorylation by protein kinase A. Biochem J 1991; 274: 387-394.
• 35 Izumi M, Yamada KM, Hayashi M. Vitronectin exists in two structurally and functionally distinct forms in human plasma. Biochim Biophys Acta 1989; 990: 101-108.
• 36 Yoneda A, Ogawa H, Kojima K. et al. Characterization of the ligand binding activities of vitronectin: interaction of vitronectin with lipids and identification of the binding domains for various ligands using recombinant domains. Biochemistry 1998; 37: 6351-6360.